The Acute Decompensated Heart Failure
National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure
A high-sodium diot is associated with acute decompensated heart failure
in ambulatory heart failure patients: a prospective follow-up study.
This study was designed to compare the safety and efficacy of levosimendan, dobutamine and placebo in patients with decompensated heart failure
To determine the effects of NT-proBNP testing on hospital length of stay as well as on 60-day morbidity and mortality in patients with acute decompensated heart failure
before and after the test was implemented in the clinical laboratory.
Clearly, a major contribution of BNP and NT-proBNP has been as an aid for the diagnosis of decompensated heart failure
in the symptomatic Emergency Medicine population.
The short-term infusion of levosimendan (Simdax[TM]), a calcium sensitizer, improves the hemodynamic function in patients with decompensated heart failure
Trevena is developing TRV027 for the intravenous hospital treatment of acute decompensated heart failure
(ADHF), and these data support the advancement of TRV027 into a future study to evaluate its clinical efficacy in patients with ADHF.
We believe that early decompression of the dilated heart can reduce myocardial injury in patients with acutely decompensated heart failure
," commented Milton Packer, M.
a clinical stage pharmaceutical company developing therapeutic agents for the treatment of acute decompensated heart failure
(ADHF) and other cardiovascular diseases, announced the presentation of a comprehensive review of the pharmacological effects of nitroxyl (HNO) in the treatment of ADHF.
NEW ORLEANS -- The investigational agent tolvaptan relieves core symptoms of acute decompensated heart failure
without inducing adverse effects, but had no impact on all-cause mortality, according to researchers in the multinational EVEREST clinical trials.
Abbott Laboratories (Abbott Park, IL) and Orion Corporation (Espoo, Finland) have expanded their licensing agreement for the injectable formulation of levosimendan (marketed as Simdax in most countries), Orion's proprietary drug for the treatment of acutely decompensated heart failure
In brief, patients 35-85 years of age admitted to hospital or seen in the specialist cardiology outpatient clinic with decompensated heart failure
with ejection fractions <40% were recruited to the study.
Trevena is developing TRV027 for the treatment of acute decompensated heart failure
Food and Drug Administration (FDA), together with the protocol for a Phase 2 clinical study in patients hospitalized for acute decompensated heart failure
a clinical stage pharmaceutical company developing therapeutic agents for the treatment of cardiovascular disease, has announced the initiation of a Phase I/IIa dose-escalation study of lead drug candidate, CXL-1020, for the treatment of acute decompensated heart failure